Investment conclusionACCUMULATE SELECTIVELYConviction: High
Accumulate selectively at S$1.53. UltraGreen combines a recurring regulated consumable, 85% gross margin, 13% FY2025 vial growth and a substantial net-cash balance sheet. At roughly 20–21x normalized FY2025 earnings and 17–19x a conservative FY2026 range, the core ICG franchise can support a 10%–14% three-to-five-year return if volume and pricing remain durable. The data/AI platform is treated as unproven optionality, not as current software value; US pricing, distributor concentration and adjacent-investment discipline are the principal risks.
- Price used
- S$1.53
- Base-case IRR
- 10%–14%
- Horizon
- 3–5 years
- Portfolio role
- Healthcare growth compounder
Principal risk: US pricing and distributor concentration: the top three customers represented about 68% of FY2025 group revenue.
2. Quick metrics
Price (28 Jul 2026)S$1.53
Income yield0% current; no fixed dividend policy
Base-case IRR10%–14%
Normalized FY2025 P/E≈20–21x
Indicative FY2026 P/E≈17–19x
Operating cash flowUS$53.3m
3. What the company does
Business overview
UltraGreen.ai is a Singapore-listed, US-dollar-reporting fluorescence-guided surgery company. Its economic core is recurring sales of IC-Green and Verdye indocyanine-green vials used with near-infrared surgical imaging systems. The Americas supplied about US$106.5 million, or 75%, of FY2025 group revenue. Imaging systems, perfusion quantification, cloud software and wearable-biosensor distribution are early platform extensions rather than established earnings engines.
How it makes money
- Sells regulated ICG pharmaceutical vials through hospital and distributor channels; repeat procedure use, price and vial volume drive the core economics.
- Uses regulatory approvals, clinical evidence, surgeon education and a dual-sourced manufacturing network to expand indications and geographies.
- Offers IC-Flow imaging systems to broaden access to fluorescence-guided surgery and reinforce demand for the consumable dye.
- Develops PerfusionWorks and the UltraGreen Data Systems platform for quantitative perfusion analysis and surgical data workflows; these products remain pre-commercial or immaterial to group revenue.
- Makes selective investments in adjacent technologies including wearable cardiac biosensors and image-guided oncology, creating optionality but also capital-allocation risk.
4. Core investment thesis
1
The moat is regulated consumable adoption, not the AI label
UltraGreen earns most of its revenue from repeat ICG vial use. Multi-year pharmaceutical approvals, clinical evidence, manufacturing compliance and integration into surgeon workflows support pricing and retention more directly than the still-unproven data platform.
2
Volume, price and geography can compound together
FY2025 combined 13% vial growth with a 17% increase in average selling price, while non-US volumes grew faster than the US. The base case requires continued procedure penetration and international approvals without assuming another large annual pricing step.
3
Net cash funds expansion but raises the capital-allocation test
The IPO left a substantial cash balance and little financial risk. Management is now funding software, imaging, biosensors and minority investments; these extensions must demonstrate clinical fit, revenue and cash returns rather than merely broadening the story.
4
Software is upside only after commercial proof
UGDS produced immaterial FY2025 revenue and a segment loss, while PerfusionWorks is still moving through regulatory pathways. The valuation assigns little current value to software until paying sites, recurring revenue and margins are disclosed.
5. Main earnings drivers
Each row links an economic variable to the earnings mechanism, the assumption embedded in the base case and the company-specific KPIs that can validate or disprove it.
| Driver | How it changes earnings | Current direction | Base-case assumption | Key measurable indicators |
|---|---|---|---|---|
| Underlying ICG vial volume | Each additional fluorescence-guided procedure generally consumes a regulated vial, so procedure penetration, new indications and geographic approvals translate directly into recurring revenue. | Positive; quarterly base distorted | Underlying volume grows 8%–11% annually after removing the 1Q2025 backlog-fulfilment distortion. |
|
| Average selling price and mix | With gross margin near 85%, price and regional mix have high incremental profit sensitivity. Price creates value only if volume and distributor relationships remain durable. | Positive carryover from FY2025 | The FY2025 US increase contributes a full year, followed by more normal price growth without material volume loss. |
|
| Regulatory and clinical adoption | Approvals open markets and indications; clinical evidence, guidelines and education convert approval into routine use. Long registration timelines are both a moat and a growth bottleneck. | Expanding | Several Asian and Middle Eastern approvals progress, with commercial ramp gradual rather than immediate. |
|
| Supply-chain resilience | API or lyophilisation disruption can prevent vial shipment despite demand. Dual sourcing and redundant facilities protect revenue and working capital. | Improving | Two API sources and multiple qualified facilities support demand without a repeat of the 2024 disruption. |
|
| Platform economics and capital allocation | IC-Flow, UGDS, PerfusionWorks and adjacent investments can increase vial use or create new revenue, but development expense and capital deployment reduce returns until commercial proof appears. | Investment rising; returns unproven | Core ICG funds measured investment; no material software profit is required for the base case. |
|
6. Evidence for and against the thesis
This table tests each thesis claim with both supporting and disconfirming evidence. Confidence refers to the evidence currently available, not the attractiveness of the share price.
| Thesis claim | Evidence supporting it | Contradictory evidence or unresolved issue | Confidence |
|---|---|---|---|
| The core ICG franchise has regulatory and workflow durability |
|
| High |
| International growth can reduce concentration |
|
| Medium–High |
| Current valuation is supported by normalized core earnings |
|
| Medium–High |
| The data and AI platform can deepen the ecosystem |
|
| Medium–Low |
| The balance sheet enables value-accretive growth |
|
| Medium |
7. Financial and margin profile
| Metric | Current | Interpretation |
|---|---|---|
| FY2025 group revenue | US$142.4m | +24%; continuing operations were US$137.9m, +28% |
| FY2025 vial volume / ASP | 988k / ≈US$138 | +13% volume and +17% average selling price |
| Adjusted EBITDA | US$89.4m | 62.8% margin; includes the small disposed UltraLinQ contribution |
| Normalized NPAT | US$63.8m | Before US$11.8m net exceptional gain; UltraLinQ contributed about US$0.8m before disposal |
| Operating cash flow | US$53.3m | After tax and working-capital outflow; about US$45m after tangible and intangible additions |
| Net cash at FY2025 | US$176.1m | Before 2026 buybacks and strategic investments |
| 1Q2026 vial shipments | ≈280.9k | +7.8% quarter on quarter; year-on-year comparison was distorted by prior backlog fulfilment |
| FY2026 revenue guidance | US$170m–US$190m | +19% to +33%; 1H2026 results due 12 Aug 2026 |
Margins and operating leverage
- FY2025 gross margin was 85.0% and adjusted EBITDA margin was 62.8%, reflecting a high-value regulated consumable with substantial operating leverage.
- Normalized net margin fell to 44.8% from 48.8% because administration, regulatory, commercial and platform investment grew faster than revenue.
- The US price increase provides a favorable FY2026 carryover, but the base case assumes some reinvestment and does not extrapolate peak incremental margins.
- UGDS generated only about US$0.4 million of FY2025 external revenue and a US$1.6 million segment operating loss; software is not yet a demonstrated margin contributor.
8. Balance sheet & capital allocation
- Operating cash flow
- US$53.3m
- Net cash at FY2025
- US$176.1m
Capital-allocation priorities and catalysts
- 1H2026 results on 12 August confirming revenue guidance, margins and cash conversion
- Additional Verdye / IC-Green approvals and measurable non-US commercial traction
- EU MDR or FDA milestones for PerfusionWorks with disclosed launch economics
- Evidence that IC-Flow placements accelerate recurring vial use
- Disciplined buybacks below intrinsic value without weakening strategic flexibility
9. Valuation summary
| Metric | Current / normalized | Interpretation |
|---|---|---|
| Normalized FY2025 P/E | ≈20–21x | S$1.53 converted at approximately S$1.30/US$; uses about 1.103bn shares and excludes the disposal gain |
| Indicative FY2026 P/E | ≈17–19x | Squad estimate using US$70m–US$78m normalized NPAT; not company guidance |
| EV / adjusted EBITDA | ≈12–13x | Uses year-end net cash, adjusted for modest 2026 deployment only approximately |
| Normalized FCF yield | ≈3%–4% | FY2025 operating cash flow less tangible and intangible additions; working capital can vary |
| Preferred framework | P/E + FCF yield + volume/ASP durability | Assign little value to pre-commercial software until revenue and economics are disclosed |
10. Return scenarios (3–5 years)
| Scenario | Assumptions | Indicative annual return |
|---|---|---|
| Bear | Underlying vial growth slows below 5%, US pricing meets resistance, investments hold normalized margin near 38% and the exit P/E falls to 14–15x. No software value is assumed. | -4% to +2% annualised |
| Base | Vial volume grows 8%–11%, pricing normalises after the FY2025 step-up, normalized EPS compounds about 10%–12%, cash remains net positive and the exit P/E is 18–20x. | 10%–14% annualised |
| Bull | International adoption and indications sustain mid-teens volume growth, margin remains above 45%, IC-Flow and software add credible revenue and the exit P/E is 22–24x. | 18%–23% annualised |
Squad Capital estimates, not company guidance. Refresh when price, normalized earnings or risk changes materially.
11. Key risks
- US pricing and distributor concentration: the top three customers represented about 68% of FY2025 group revenue
- Regulatory, product-quality or manufacturing disruption affecting a concentrated product franchise
- Volume normalization after backlog fulfilment or resistance to the FY2025 US price increase
- Capital diverted into UGDS, biosensors and minority investments before commercial returns are proven
- Majority-shareholder control, limited free float and low secondary-counter liquidity
- No fixed dividend policy and foreign-exchange exposure between USD reporting, EUR operations and SGD share purchases
Thesis breakers
- Underlying vial growth remains below 5% or price increases cause sustained share loss
- Gross margin falls below 80% without a deliberate and high-return mix change
- Operating cash conversion remains below 70% of normalized NPAT for several periods
- Net cash is deployed into unrelated or low-return investments faster than the core franchise can absorb
- A material regulatory, quality or supply event interrupts ICG availability
12. Thesis monitoring dashboard
Only indicators capable of materially changing the forecast, risk assessment or investment conclusion are included here.
| Thesis-critical indicator | Current reading | Base-case requirement | Status |
|---|---|---|---|
| Underlying vial volume growth | 1Q2026 shipped about 280.9k vials, +7.8% sequentially; reported year-on-year comparison includes prior backlog effects | 8%–11% underlying annual growth after normalisation | On track |
| ASP, retention and gross margin | FY2025 ASP +17%; gross margin 85.0% | Volume remains durable and gross margin stays above 82% after the US price increase | On track |
| Normalized profit and cash conversion | FY2025 normalized NPAT US$63.8m versus operating cash flow US$53.3m | Operating cash flow averages at least 75%–80% of normalized NPAT through the growth cycle | Watch |
| Net cash and adjacent investment | US$176.1m at FY2025 before 2026 buybacks and strategic investments | Remain strongly net cash while each material investment has a disclosed strategic and return case | Watch |
| UGDS / PerfusionWorks commercial proof | UGDS FY2025 external revenue about US$0.4m and segment operating loss about US$1.6m | Regulatory approval, paying sites and recurring revenue disclosed before assigning meaningful software value | Unproven |
| Valuation versus evidence | S$1.53 on 28 Jul; roughly 20–21x FY2025 normalized earnings | Multiple remains at or below the high teens on forward normalized earnings, or growth evidence strengthens | Price-dependent |
13. Primary sources
14. Revision history
| Date | Price | View | What changed |
|---|---|---|---|
| 2 Aug 2026 | S$1.53 (28 Jul close) | Accumulate selectively | First current publication. Revalidated FY2025, 1Q2026 volumes, current price, share count, cash flow, customer concentration and platform economics. Prior chat conclusions were used only as questions; software is treated as unproven optionality. |
| Earlier chat research | — | Research lead | The earlier discussion about UltraLinQ, team location and the cloud platform was preserved in a linked evidence/FAQ note and not carried forward as a current investment conclusion. |